Brind.

Bristol Myers Squibb presented real-world outcomes data at the European Society of Cardiology congress.

3 reports, 1 independent Updated Aug 29

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bristol Myers Squibb presented real-world outcomes data at the European Society of Cardiology congress.

Who's involved

What this event is mainly about

European Society of Cardiology Bristol-Myers Squibb

Keep exploring

The entities involved

European Society of Cardiology
non-profit knowledge-based professional association
- Nathif Adan Jama presented and published AMALFI results at the European Society of Cardiology.Sun 02:55
Bristol-Myers Squibb
American pharmaceutical company
- Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09

Related events

Coverage

Newest first; wire copies grouped

Aug 29Business WireBristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 Findings from COLLIGO-HCM reinforce Camzyos’
Aug 25Business WireBristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025 Camzyos (mavacamten) presentations include real-world outcomes from COLLIGO-HCM an

1 more outlet ran the same wire story

Aug 29finanznachrichten.de